MedTrace Logo

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

NCT06913023 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-04-06

No results posted yet for this study

Summary

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Conditions

  • Kidney Transplant Recipient

Interventions

DRUG

Semaglutide 3 MG [Rybelsus]

Semaglutide 3mg for 4 weeks.

DRUG

Semaglutide 7 MG [Rybelsus]

Semaglutide 7mg for 4 weeks.

DRUG

Semaglutide 14 MG [Rybelsus]

Semaglutide 14mg for 16 weeks.

DRUG

Placebo Oral Tablet

Placebo tablet

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Sunita Singh, MD MSc FRCPC · University Health Network, Toronto General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06913023 on ClinicalTrials.gov